15 trial(s) found.

Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors (NVL-655-EAP)

NSW2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (AVAILABLE)

VIC3000 - Melbourne - Peter MacCallum Cancer Centre (AVAILABLE)

NCT06707610

A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors (ALK202-01)

NCT06656390

A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors (ALK201-01)

NCT06624059

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status (HORIZON-2)

NCT05987332

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) (IDE196-002)

NCT05384626

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1) (NVL-655-01)

NCT05170204

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (HORIZON-1)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (WITHDRAWN)2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)

NZNZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (WITHDRAWN)

NCT04774718

A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available (GO42286)

NCT04094610

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (CA127-1029)

NCT03947385

A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (IDE196-001)

NCT03093116

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)

VIC3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3002 - East Melbourne - Epworth Freemasons (COMPLETED)

SA5042 - Bedford Park - Flinders Medical Centre (COMPLETED)

NCT02645149

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

ACTRN12621000991819

Not Applicable

A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (PDCCiHNC)

ACTRN12621000312842

A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling (MoST-Addendum-14)

ACTRN12616001187437

Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing. (MatchMel)

Filters

Recruitment Status

Recruitment Country and State

Phase

Trial Type

Cancer Therapy Class

ALK	87%
ROS1	60%
RET	33%
MET	27%
TRK	20%
MEK	20%
CDK4	20%
CDK6	20%
FGFR2	13%
PD-1/PD-L1	13%
PKC	13%
IGF1R	13%
BCR-ABL1	13%
CRAF	13%
EGFR	13%
FLT3	13%
KIT	13%
PDGFR	13%
PDGFRA	13%
RAF	13%
SRC	13%
VEGFR	13%
YES1	13%
mTOR	13%
mTORC1	13%
FGFR2b	7%
CTLA4	7%
PD-1	7%
PD-L1	7%
ATR	7%
JAK1	7%
JAK2	7%
PI3K	7%
SMO	7%
mTORC2	7%
AXL	7%
ERBB2	7%
FGFR1	7%
FGFR1/2/3	7%
FGFR3	7%
FGFR4	7%
HDAC	7%
PARP	7%
VEGFR2	7%
proteasome	7%

Facility

Cancer Type

ARTICANZ - Beta (ver 0.91)

Search results

target/ALK

Filters